Fluorinated molecules have a wide range of applications and are used as medicines,
agrochemicals and refrigerants and in smartphone liquid crystal displays, photovoltaic solar …

Parkinson's disease (PD), as the second most common neurodegenerative disease, is
caused by complex pathological processes and currently remains very difficult to treat. PD …

Inhibition of the kinase activity of leucine-rich repeat kinase 2 (LRRK2) is under investigation
as a possible treatment for Parkinson's disease. However, there is no clinical validation as …

Over the past 15 years protein kinases have become the pharmaceutical industry's most
important class of drug target in the field of cancer. Some 20 drugs that target kinases have …

Drug discovery and development is a complex and lengthy enterprise that suffers from high
rates of candidate attrition at all stages of the process. The physical, biological, and …

LRRK2 is one of the most promising drug targets for Parkinson's disease. Though type I
kinase inhibitors of LRRK2 are under clinical trials, alternative strategies like type II inhibitors …

The kinase-activating mutation G2019S in leucine-rich repeat kinase 2 (LRRK2) is one of
the most common genetic causes of Parkinson's disease (PD) and has spurred development …

Leucine-rich repeat kinase 2 (LRRK2) is a multifunctional protein that orchestrates a diverse
array of cellular processes, including vesicle transport, autophagy, lysosome degradation …

Great successes have been achieved in developing small-molecule kinase inhibitors as
anticancer therapeutic agents. However, kinase deregulation plays essential roles not only …

Leucine rich repeat kinase 2 (LRRK2) has been genetically linked to Parkinson's disease
(PD) by genome-wide association studies (GWAS). The most common LRRK2 mutation …